AOD-9604 vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist — a 31-amino acid peptide analog of human glucagon-like peptide-1 (GLP-1) with a 94% sequence homology to native GLP-1. It is FDA-approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Semaglutide has an albumin-binding fatty acid side chain that extends its half-life to approximately 7 days, enabling once-weekly dosing. It is the most widely prescribed GLP-1 medication globally, with over 25 million Americans expected to be on GLP-1 therapy by 2030.
Full details →Side-by-Side Comparison
| Aspect | AOD-9604 | Semaglutide |
|---|---|---|
| Mechanism | Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors. | Semaglutide binds to and activates the GLP-1 receptor, a G-protein coupled receptor expressed in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract. This triggers multiple downstream effects: (1) glucose-dependent insulin secretion from pancreatic beta cells, (2) suppression of glucagon release from alpha cells, (3) delayed gastric emptying, slowing nutrient absorption, (4) central appetite suppression via hypothalamic GLP-1 receptors, reducing hunger and increasing satiety. The peptide features a C-18 fatty diacid moiety attached via a linker to Lys26, enabling non-covalent albumin binding that protects against DPP-4 degradation and renal clearance. |
| Typical Dosage | Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg. | For weight management (Wegovy): start at 0.25 mg weekly for 4 weeks, escalate to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg weekly. Each escalation lasts 4 weeks. Maintenance dose is 2.4 mg weekly. For type 2 diabetes (Ozempic): start at 0.25 mg weekly for 4 weeks, increase to 0.5 mg. May increase to 1 mg, then 2 mg if additional glycemic control is needed. Oral semaglutide (Rybelsus): 3 mg daily for 30 days, then 7 mg daily. May increase to 14 mg daily. Oral Wegovy: 3 mg daily for 4 weeks, escalate to 7 mg, 14 mg, and 25 mg daily. Take on empty stomach with no more than 4 oz of water, 30 minutes before food. |
| Administration | Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects. | Injectable: subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Store pens refrigerated (36-46°F) before first use; after first use, store at room temperature or refrigerated for up to 56 days. Oral: take on an empty stomach with a sip of plain water (no more than 4 oz). Wait at least 30 minutes before eating, drinking, or taking other oral medications. Do not split, crush, or chew tablets. |
| Side Effects | Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH. | Very common (>10%): nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain. These are typically mild-to-moderate and decrease over time with dose escalation. Common (1-10%): headache, fatigue, dyspepsia, dizziness, bloating, flatulence, GERD, gastroenteritis. Notable: 'Ozempic face' (facial volume loss due to rapid weight loss), hair loss (telogen effluvium, reported in 25-33% of users in some studies), injection site reactions. |
| Best For |
Key Differences
Unique to AOD-9604:
Unique to Semaglutide:
Detailed Analysis
Commonalities
Both AOD-9604 and Semaglutide are commonly used for Fat Loss.
Which Should You Choose?
Semaglutide has stronger evidence for Fat Loss.
Ready to Learn More?
Looking for trusted sources?